AI In Clinical Trial Supply Chains

A conversation with Daniel Burrus, founder, Burrus Research

Artificial intelligence is rapidly moving from experimentation to operational reality across the life sciences industry. Yet for clinical trial supply organizations, the challenge is not simply adopting new technology. It is determining how AI can create meaningful value within environments defined by protocol-driven constraints, uncertain demand, global distribution networks, manufacturing lead times, regulatory requirements, and patient-centric decision-making.

As organizations explore AI-enabled forecasting, scenario modeling, inventory optimization, and decision support, an important question remains: Will AI help supply leaders make better decisions or simply make existing processes move faster? The answer may depend less on the technology itself and more on how organizations approach uncertainty, assumptions, and the future.

In this Q&A, Elizabeth Urbanek, executive editor of Clinical Supply Leader, speaks with Daniel Burrus, founder of Burrus Research and a globally recognized futurist, about what Burrus calls the Hard and Soft Trends shaping AI adoption, the risks of relying on correlation without operational context, the challenges of integrating AI across fragmented systems, and what separates truly Anticipatory Organizations from those simply deploying new tools. Together, they explore what clinical trial supply leaders should watch for as AI becomes an increasingly embedded part of planning and execution.

Clinical trial supply chains are highly constrained by protocol design, manufacturing lead times, and regulatory variability. From a futurist perspective, what “Hard Trends” do you see shaping how AI will realistically integrate into these systems over the next five to 10 years?

From my perspective, the first Hard Trend is that AI will become increasingly embedded into every business process, including highly regulated supply chains. That does not mean AI will replace experienced professionals. It means AI will increasingly augment their ability to see patterns, anticipate problems, and make better decisions faster.

A second Hard Trend is the growing datafication of operations. Every organization is generating more data from more sources every year. The opportunity is not simply to collect more data; it is to turn that data into actionable foresight.

The third Hard Trend is increasing regulation and governance around AI. In a regulated environment, AI will not reduce the need for transparency, validation, and accountability. It will increase the need for all three.

These trends will become particularly important as trial designs grow more complex, patient populations become more targeted, and supply networks support more countries, more SKUs, and more specialized manufacturing models. The organizations that can use AI to interpret enrollment signals, manage shorter planning windows, and anticipate supply constraints across global networks will have a distinct advantage. The Soft Trend is whether organizations apply AI wisely. AI can help leaders anticipate problems earlier, model different scenarios, and make more confident decisions. But if AI is used as a black box, or if it is disconnected from the real-world constraints of the business, it will create a false sense of certainty.

The question is not, “Will AI be used?” It will. The better question is, “Will we use AI to become more anticipatory, or will we use it to make reactive decisions faster?”

AI is increasingly being applied to forecasting and optimization in clinical trial supply. Where do you see a risk of organizations mistaking correlation-driven outputs for true operational intelligence in environments defined by strict protocol logic?

I see the risk beginning when leaders confuse more data with better foresight.

AI can find correlations very quickly, but correlation is not the same as intelligence. In a highly constrained environment, an AI system may identify a pattern that looks useful but fails to reflect the rules, limits, and realities that govern actual decisions.

That is why assumptions matter. In my work, I separate Hard Trends from Soft Trends. A Hard Trend is a future fact. A Soft Trends is a future maybe, often based on assumptions. If leaders do not know which assumptions are built into an AI recommendation, they may treat a Soft Trend as if it were a Hard Trend. That is where risk increases.

For example, a model may identify a correlation between historical enrollment activity and drug demand, yet fail to account for country activation delays, randomization patterns, protocol amendments, or shelf life limitations. What appears to be a valid forecast can quickly become unreliable if the underlying operational constraints are not part of the equation.

AI should be used as augmented thinking, not outsourced thinking. It should help leaders ask better questions, test assumptions, and see risk earlier. It should not become a black box that produces confidence without clarity.

The danger is not simply that AI can be wrong. The bigger danger is that it can be wrong at scale.

Many clinical trial supply decisions still depend on fragmented systems (RTSM, ERP, IRT, and depot planning tools). How should leaders think about integrating AI across these disconnected workflows without introducing new layers of uncertainty?

I would start by saying fragmentation is not only a technology problem. It is a decision problem.

When different systems hold different pieces of the truth, adding AI on top of that fragmentation can create the appearance of intelligence without actually reducing uncertainty. In some cases, it may increase it.

Leaders should begin with the decisions they want to improve, not with the technology they want to deploy. What decisions need to be made earlier? What problems are predictable? What recurring delays, shortages, waste, or compliance risks could be identified before they occur?

On a practical level, one system may show accelerating enrollment, another may show constrained inventory, and a third may indicate manufacturing capacity limitations. The value of AI is not that it replaces those systems. The value is its ability to reconcile conflicting signals, identify emerging risks, and present a more complete picture of what happens next if no action is taken.

Once those questions are clear, AI can be integrated around decision improvement rather than system automation.

The goal is not to add another layer of software. The goal is to create a more unified view of the future so leaders can act earlier, with greater confidence and lower risk.

In your view, what distinguishes organizations that are becoming “anticipatory” in clinical trial supply chain management from those simply adopting AI tools without changing underlying decision structures?

What distinguishes organizations that are becoming anticipatory is mindset before technology.

An organization that is simply adopting AI asks, “Where can we use this tool?” An Anticipatory Organization asks, “What future problems can we identify and pre-solve before they disrupt performance?”

That is a very different question. AI adoption often focuses on efficiency. Anticipatory thinking focuses on certainty, risk reduction, and better timing. It asks leaders to separate what will happen from what might happen, then act on the areas where they have the greatest certainty.

An anticipatory approach might identify that enrollment is trending ahead of plan, that depot inventory will be depleted earlier than expected, or that a manufacturing campaign will not support projected demand six months from now. Those insights create time to adjust production, rebalance inventory, or revise supply strategies before patients are impacted.

In this context, increasing use of AI, growing data, rising complexity, and increasing governance are Hard Trends. They will continue. The outcomes, however, are Soft Trendss. Better planning, reduced waste, improved visibility, and stronger decision-making are not guaranteed. Leaders have to shape those outcomes.

An Anticipatory Organization does not use AI merely to react faster. It uses AI to see the future earlier.

Clinical trials often require balancing efficiency with overage risk, patient protection, and regulatory compliance. How should AI be applied in a way that enhances decision confidence without obscuring these trade-offs?

AI should make trade-offs more visible, not less visible.

In any complex supply chain, the most efficient decision is not always the best decision. A lower-cost option may create more risk. A faster option may reduce flexibility. A plan that looks optimized on paper may not be resilient in the real world.

In clinical trials, leaders regularly balance inventory overage against waste, rapid shipment options against cost, and aggressive forecasts against the consequences of a patient-facing shortage. AI creates the most value when it makes those competing variables more transparent so decision makers can evaluate the consequences of each option before committing to a course of action.

AI creates value when it helps leaders see options, consequences, assumptions, and risk earlier. It should improve the quality of human judgment, not replace it.

This is where I would apply what I call a pre-mortem. Before executing a decision, use AI to help identify what could go wrong, where the weak assumptions are, and what problems can be solved in advance.

That is how AI increases confidence: not by hiding complexity but by exposing it early enough to do something about it.

Looking ahead, what early signals should clinical trial supply leaders watch for that indicate AI is moving from experimental use cases into a truly embedded decision layer within trial supply planning and execution?

I recommend watching for several signals.

First, AI will move from isolated pilots to everyday workflows. It will no longer sit outside the process as an experiment. It will become part of how decisions are made.

Second, leaders will demand explainability. They will not only ask what AI recommends. They will ask why it recommends it, what assumptions it used, and what risks are attached to the recommendation.

Third, AI will increasingly support decisions in real time or near real time. As data grows and analytics improve, waiting for periodic reviews will feel too slow.

Fourth, organizations will become clearer about decision rights. They will define what AI can recommend, what it can automate, and what must remain a human decision. You will also see AI become embedded in core planning activities such as demand forecasting, depot replenishment, production scheduling, expiry risk management, and protocol change impact assessments. When these capabilities are part of routine decision-making rather than stand-alone analysis projects, the transition from experimentation to operational deployment is well underway.

Finally, AI will move from operational problem-solving to strategic foresight. When leaders use AI to anticipate future constraints, model scenarios, and pre-solve problems before they occur, AI has moved beyond experimentation.

That is when AI becomes more than a tool. It becomes part of an anticipatory capability.

About The Contributor:

Daniel Burrus is an AI advisor, global futurist, business strategist, best-selling business author, and CEO of Burrus Research. He is the creator of the Hard Trend Methodology and the Anticipatory Organization® Model, helping leaders identify future certainties, anticipate disruption, and turn accelerating technological change into strategic advantage. Download his latest AI Strategy Report at www.aiStrategyReport.com.